Evidence map›Paper›PMID 24556554›Full record

ArticleMethods (San Diego, Calif.)2014

Targeted genome editing in Aedes aegypti using TALENs.

Azadeh Aryan, Kevin M Myles, Zach N Adelman

Open access · greenAbstract read
In one paragraph

Article in Methods (San Diego, Calif.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Germline Cas9 expression yields highly efficient genome engineering in a major worldwide disease vector,Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Azadeh AryanFralin Life Science Institute, Dept. of Entomology, Virginia Tech, Blacksburg, VA 20461, United States.
Kevin M MylesFralin Life Science Institute, Dept. of Entomology, Virginia Tech, Blacksburg, VA 20461, United States.
Zach N AdelmanFralin Life Science Institute, Dept. of Entomology, Virginia Tech, Blacksburg, VA 20461, United States. Electronic address: zachadel@vt.edu.
Virginia Tech · US

Funding

Antiviral Pathways in Disease Vector MosquitoesR01AI085091 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI ADELMAN, ZACH N. · 2010 to 2014
$1.9M
Recombination-mediated cassette exchange in Aedes aegypti mosquitoesR21AI099843 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI ADELMAN, ZACH N. · 2012 to 2013
$430k
NIAID NIH HHS AI085091NIAID NIH HHS AI099843NIAID NIH HHS R01 AI085091NIAID NIH HHS R21 AI099843
6 · The paper itself

Abstract

The Culicine mosquito, Aedes aegypti, is both a major vector of arthropod-borne viruses (arboviruses) and a genetic model organism for arbovirus transmission. TALE nucleases (TALENs), a group of artificial enzymes capable of generating site-specific DNA lesions, consist of a non-specific FokI endonuclease cleavage domain fused to an engineered DNA binding domain specific to a target site. While TALENs have become an important tool for targeted gene disruption in a variety of organisms, application to the mosquito genome is a new approach. We recently described the use of TALENs to perform heritable genetic disruptions in A. aegypti. Here, we provide detailed methods that will allow other research laboratories to capitalize on the potential of this technology for understanding mosquito gene function. We describe target site selection, transient embryo-based assays to rapidly assess TALEN activity, embryonic microinjection and downstream screening steps to identify target site mutations.

Indexed as

AedesAnimalsDeoxyribonucleasesEmbryo, NonmammalianFemaleMaleMicroinjectionsMutagenesis, Site-DirectedDeoxyribonucleasesAedes aegyptiGene editingMeganucleaseMosquitoTALE effectorTALEN

Identifiers

PMID24556554
PMCPMC4136995
OpenAlexW2088510173

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.